Morning Overview on MSN

A new two-pill combo just slashed LDL cholesterol by 48.6% in a phase 3 trial — the sharpest drop ever logged without adding a statin to the mix

For the roughly 30 million American adults who have been told their cholesterol is too high but cannot stomach a statin, the treatment menu has been frustratingly short: a modest pill called ezetimibe ...
The New England Journal of Medicine

A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide

Enlicitide decanoate, an oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer-term data ...
Healio

PCSK9 inhibition via base editing lowers LDL in patients with genetic high cholesterol

Genetic PCSK9 inhibition via base editing appeared safe and demonstrated dose-dependent, durable reductions in PCSK9 and LDL cholesterol, researchers reported.At the highest dose, VERVE-102 (Verve ...
The New England Journal of Medicine

Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease

Despite guideline recommendations, evidence from randomized trials evaluating the appropriate low-density lipoprotein (LDL) cholesterol target for secondary prevention in patients with atherosclerotic ...
Business Wire

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef HeFH trial ...
TCTMD

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

NEW ORLEANS, LA—Lowering LDL cholesterol to less than 55 mg/dL reduces the risk of major cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD) better than does a higher ...